Epidemiology and Genetics Unit, Department of Health Sciences, University of York, Seebohm Rowntree Building, Heslington YO10 5DD, UK.
Cancer Causes Control. 2010 Dec;21(12):2079-83. doi: 10.1007/s10552-010-9626-2. Epub 2010 Aug 10.
Most non-Hodgkin lymphoma (NHL) subtypes occur more among men than women. Since sex hormones may influence immune function, female hormones may be involved. To investigate the relationship between NHL subtypes and reproductive factors, findings from a UK population-based case-control study (1998-2003) are presented.
Female cases (n = 389) and controls (n = 394) aged 16-69 reported their reproductive histories. Odds ratios (ORs) and 95% confidence intervals (CI) were computed using unconditional logistic regression.
No associations were found for age at menarche, parity, or age at first child. Among postmenopausal women, hormone therapy (HT) users had risks of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) below one compared to non-users (OR = 0.7, 95% CI 0.5,1.2; OR = 0.6, 95% CI 0.4,1.0, respectively). Estimates agree with other reports: meta-analyses gave pooled ORs of 0.8 (95% CI 0.6,0.9) for DLBCL and 1.0 (95% CI 0.8,1.2) for FL. In our study, ORs decreased with years of HT use: less and more than 5 years being 0.9 (95% CI 0.5,1.5) and 0.6 (95% CI 0.3,1.1) for DLBCL (p-trend = 0.22), and 0.8 (95% CI 0.4,1.4) and 0.4 (95% CI 0.2,0.9) for FL (p-trend = 0.06).
For greater power to investigate the association of hormones with DLBCL, FL, and rarer NHL subtypes, pooling data through the International Lymphoma Epidemiology Consortium (InterLymph) is warranted.
大多数非霍奇金淋巴瘤（NHL）亚型在男性中的发病率高于女性。由于性激素可能影响免疫功能，女性激素可能与之相关。为了研究 NHL 亚型与生殖因素的关系，现呈现一项来自英国基于人群的病例对照研究（1998-2003 年）的结果。
16-69 岁的女性病例（n=389）和对照（n=394）报告了她们的生殖史。使用非条件 logistic 回归计算比值比（OR）和 95%置信区间（CI）。
初潮年龄、产次或首次生育年龄与 NHL 无关联。在绝经后妇女中，与未使用者相比，激素治疗（HT）使用者弥漫性大 B 细胞淋巴瘤（DLBCL）和滤泡淋巴瘤（FL）的风险低于 1（OR=0.7，95%CI 0.5，1.2；OR=0.6，95%CI 0.4，1.0）。估计值与其他报告一致：荟萃分析得出 DLBCL 的汇总 OR 为 0.8（95%CI 0.6，0.9），FL 的汇总 OR 为 1.0（95%CI 0.8，1.2）。在我们的研究中，OR 随 HT 使用年限的减少而降低：使用年限少于 5 年和多于 5 年的 OR 分别为 0.9（95%CI 0.5，1.5）和 0.6（95%CI 0.3，1.1）（趋势检验 p 值=0.22），对于 FL，OR 分别为 0.8（95%CI 0.4，1.4）和 0.4（95%CI 0.2，0.9）（趋势检验 p 值=0.06）。
为了有更大的能力研究激素与 DLBCL、FL 和更罕见的 NHL 亚型的关联，通过国际淋巴瘤流行病学联盟（InterLymph）对数据进行汇总是有必要的。
